EUVIMEDEUVIMED entdecken
Vergleichsstudie

Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity

Andy Bowe, Mary Hayes, Isha John, Monica Diaz, Suzanne Dixon iD, Insiya Poonawalla

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70219 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Andy Bowe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Humana Healthcare Research, Inc, Louisville, Kentucky, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims To compare treatment persistence and augmentation in adults with type 2 diabetes initiating glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor therapy, including subgroups with cardiovascular disease and obesity. Materials and Methods Using Humana Healthcare Research claims data, we identified adults with type 2 diabetes newly initiating GLP‐1 RA or SGLT2i therapy between 1 January, 2018, and 30 June 2022. Eligible patients had >12 months of continuous enrollment before and after the index date (first GLP‐1 RA or SGLT2i claim). Persistence was measured over 12 months post‐index, defined by a therapy gap

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsObesityCardiovascular DiseasesHypoglycemic AgentsHumansFemaleMaleAgedMiddle AgedUnited StatesHeart Disease Risk Factors

Stichwörter der Autor:innen

GLP‐1SGLT2 inhibitorantidiabetic drugantiobesity drugcardiovascular diseasereal‐world evidence

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Humana Healthcare Research, Inc, Louisville, Kentucky, USA.
  • Humana Pharmacy Solutions, Humana Inc, Louisville, Kentucky, USA.

ORCID-Profile: Suzanne Dixon

Zitieren

APA

Bowe, A., Hayes, M., John, I., Diaz, M., Dixon, S., & Poonawalla, I. (2026). Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70219

Vancouver

Bowe A, Hayes M, John I, Diaz M, Dixon S, Poonawalla I. Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70219

BibTeX
@article{Bowe2026,
  author = {Bowe, Andy and Hayes, Mary and John, Isha and Diaz, Monica and Dixon, Suzanne and Poonawalla, Insiya},
  title = {Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70219}
}
Kostenlos starten →